(3) While trofinetide is described as an IGF-1 pathway modulator, the precise molecular targets, receptor interactions, and downstream signaling cascades mediating Rett syndrome efficacy remain incompletely characterized. The gene discussed is IGF1; the disease is atypical Rett syndrome.